上海复星医药（集团）股份有限公司（股票代码：02196）于2026年3月5日披露2026年2月股份变动月报。报告期为2026年2月，公司已发行股份数量和注册股本均未发生变化，整体股本规模维持不变。
报告显示，截至2026年2月28日，公司注册股本合计为人民币2,670,429,325元。其中，H股法定股本551,940,500股，A股法定股本2,118,488,825股，均与上月底持平。期末公司H股已发行股份为540,971,500股，库存股份为10,969,000股；A股已发行股份为2,098,582,573股，库存股份为19,906,252股，均无新增发行或注销。
本月内公司未进行任何购回或转让库存股份活动，亦未新增发行新股。A股期权激励计划和H股受限制股份单位计划无行权或转换行为，仅保留原有授出数量，期末A股期权数量为4,446,400份，尚未归属的H股受限制股份单位为10,382,200份。
公司声明已严格遵守香港联交所《上市规则》和相关法律法规。公告由公司H股股份过户登记处提交。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.